Innomune Tablet contains Azathioprine 50mg, an immunosuppressive agent primarily used to prevent organ transplant rejection and to manage autoimmune disorders. Azathioprine acts by inhibiting purine synthesis, thereby suppressing the proliferation of immune cells, particularly lymphocytes, which play a key role in the immune response. This mechanism helps reduce the activity of the immune system, making it effective in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel diseases like Crohn’s disease and ulcerative colitis. Innomune Tablet is typically prescribed under strict medical supervision due to its potential adverse effects, including bone marrow suppression, increased susceptibility to infections, hepatotoxicity, and gastrointestinal disturbances. Regular monitoring of blood counts, liver function tests, and renal parameters is essential during therapy to detect and manage any complications promptly. Dosage adjustments may be necessary based on therapeutic response and tolerability. Patients should be advised to avoid live vaccines and to report any signs of infection or unusual bleeding immediately. Innomune Tablet should be used cautiously in pregnancy and lactation, with benefits weighed against potential risks. Proper adherence to prescribed dosing and monitoring protocols ensures optimal therapeutic outcomes while minimizing adverse effects.